文献速递心境障碍睡眠障碍

一年体动记录研究:睡眠与静息-活动节律作为抑郁复发标志

One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in Depression.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

这项多中心观察性队列研究纳入93例基线MADRS≤14的重性抑郁障碍成人,用体动记录仪连续监测1-2年。基线睡眠规律性低、相对振幅低、睡眠效率低、入睡后觉醒高和夜间活动高与复发风险相关,时变模型中相位偏差大和相对振幅低也与复发相关。体动记录参数有潜力作为识别抑郁复发高危个体的可扩展生物标志物。

要点

  • 基线睡眠规律性低、相对振幅低、睡眠效率低与抑郁复发风险升高相关。
  • 基线入睡后觉醒高和夜间活动高与抑郁复发风险升高相关。
  • 时变模型中相位偏差增大和相对振幅降低与复发相关,相对振幅在校正同期MADRS后仍显著。

核心结论

  • 体动记录仪测量的睡眠相位变异性和日常活动振幅与抑郁复发相关,支持其作为识别高危个体和实现及时个体化复发预防的潜在可扩展生物标志物。

研究设计与样本

  • 多中心观察性队列研究,数据收集于2016年7月至2019年1月,从加拿大门诊精神科和初级保健诊所转诊样本中随访1至2年。
  • 体动记录参数连续测量1至2年,每2周平均一次;主要结局为复发,由独立小组裁定,定义为MADRS评分大于或等于22持续2周、精神科住院、出现自杀意图或行为、或抗抑郁药治疗升级中的任一情况。

主要发现

  • 在校正年龄、性别、季节和基线MADRS评分的Cox模型中,基线较低的睡眠规律性(HR,0.46;95%CI,0.28-0.74;P=.002)、较低的相对振幅(HR,0.45;95%CI,0.29-0.70;P<.001)、较低的睡眠效率(HR,0.57;95%CI,0.38-0.85;P=.005)、较高的入睡后觉醒(HR,1.77;95%CI,1.12-2.80;P=.01)和较高的夜间活动(HR,1.86;95%CI,1.32-2.62;P<.001)与复发相关。
  • 在时变模型中,较大的复合相位偏差(HR,1.76;95%CI,1.04-2.98;P=.04)和较低的相对振幅(HR,0.45;95%CI,0.21-0.97;P=.046)与复发相关,相对振幅在校正同期MADRS评分后仍显著(HR,0.60;95%CI,0.36-0.98;P=.04)。
  • 体动记录仪显著区分了经历复发的个体与临床病程超稳定(MADRS评分始终<14)和不稳定(短暂MADRS评分14-22但无复发)的个体。

关键数值与推荐

  • 复发裁定标准:MADRS评分大于或等于22持续2周、精神科住院、出现自杀意图或行为、或抗抑郁药治疗升级中的任一情况。
  • 基线纳入标准:重性抑郁障碍诊断且MADRS评分小于或等于14。

临床怎么用

  • 体动记录仪测量的睡眠规律性、相对振幅、睡眠效率、入睡后觉醒和夜间活动等参数可用于识别抑郁复发高危个体。
  • 监测睡眠相位变异性和日常活动振幅的变化可能有助于及时启动个体化复发预防措施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Given its recurrent nature and burden, major depressive disorder (MDD) warrants reliable methods of relapse prediction. OBJECTIVE: To determine whether actigraphy-derived parameters, measured over 1 to 2 years, are associated with relapse. DESIGN, SETTING, AND PARTICIPANTS: This was an observational cohort study with data collection from July 2016 to January 2019. The setting was multicentric. A referred sample of participants from outpatient psychiatric and primary care clinics across Canada were followed up for 1 to 2 years. Participants had a diagnosis of MDD and Montgomery-Åsberg Depression Rating Scale (MADRS) score less than or equal to 14 at baseline. EXPOSURES: Actigraphy-derived parameters measured over 1 to 2 years. MAIN OUTCOME AND MEASURES: The primary outcome was relapse, defined as any of the following: MADRS score greater than or equal to 22 for 2 consecutive weeks, psychiatric hospitalization, emergence of suicidal intent or behavior, or antidepressant treatment escalation-all adjudicated by an independent panel. Continuous actigraphy data were averaged every 2 weeks. RESULTS: From a referred sample of 102 adults, 93 participants (mean [SD] age, 39.1 [12.7] years; 58 female [62%]) contributed approximately 32 000 complete actigraphy days (median, 46 weeks). In Cox models adjusted for age, sex, season, and baseline MADRS score, baseline lower sleep regularity (hazard ratio [HR], 0.46; 95% CI, 0.28-0.74; P = .002), lower relative amplitude (RA; HR, 0.45; 95% CI, 0.29-0.70; P < .001), lower sleep efficiency (HR, 0.57; 95% CI, 0.38-0.85; P = .005), higher wake after sleep onset (HR, 1.77; 95% CI, 1.12-2.80; P = .01), and higher nighttime activity (HR, 1.86; 95% CI, 1.32-2.62; P < .001) were associated with relapse. In time-varying models, greater composite phase deviation (HR, 1.76; 95% CI, 1.04-2.98; P = .04) and lower RA (HR, 0.45; 95% CI, 0.21-0.97; P = .046) were associated with relapse, with RA remaining significant even after adjusting for concurrent MADRS scores (HR, 0.60; 95% CI, 0.36-0.98; P = .04). Actigraphy significantly differentiated individuals experiencing relapse from those with an ultrastable (MADRS score <14 throughout) and unstable (transient MADRS score, 14-22 without relapse) clinical course. CONCLUSIONS AND RELEVANCE: Actigraphy measures of sleep phase variability and daily activity amplitude were associated with depressive relapse, supporting actigraphy as a potential scalable biomarker to identify high-risk individuals and enable timely, personalized relapse prevention in MDD.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tonon AC, Nexha A, Cunningham JEA, et al. One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in Depression. JAMA Psychiatry. 2026. PMID: 41670991. doi:10.1001/jamapsychiatry.2025.4453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。